LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Larimar Therapeutics today and set a price target of $33.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors related to Larimar Therapeutics’ prospects. The survey conducted among physicians managing Friedreich’s ataxia (FA) patients indicates a cautiously positive sentiment towards Larimar’s nomlabofusp, with a notable percentage of physicians expressing satisfaction with its risk/benefit profile. This is despite some concerns about safety, such as instances of anaphylaxis, which do not seem to be major deterrents for prescribers or the FDA.
Furthermore, the potential for nomlabofusp to provide meaningful cardiac and neurological benefits is seen as promising, with many physicians optimistic about its efficacy. The survey results suggest that, if approved, a significant portion of eligible patients could be treated with nomlabofusp in combination with the existing therapy, Skyclarys. These factors, combined with the current market dynamics and physician sentiment, contribute to the Buy rating for Larimar Therapeutics’ stock.
In another report released yesterday, Guggenheim also reiterated a Buy rating on the stock with a $26.00 price target.